March 
13th
 at 
6:00pm

Accelerating BioVenture Innovation Kickoff

Caption

R. Harrison

Clear your calendar - It's going down! Splash Blocks kicks off on April 21st, and you're invited to take part in the festivities. Splash HQ (122 W 26th St) is our meeting spot for a night of fun and excitement. Come one, come all, bring a guest, and hang loose. This is going to be epic!

Clear your calendar - It's going down! Splash Blocks kicks off on April 21st, and you're invited to take part in the festivities. Splash HQ (122 W 26th St) is our meeting spot for a night of fun and excitement. Come one, come all, bring a guest, and hang loose. This is going to be epic!

Clear your calendar - It's going down! Splash Blocks kicks off on April 21st, and you're invited to take part in the festivities. Splash HQ (122 W 26th St) is our meeting spot for a night of fun and excitement. Come one, come all, bring a guest, and hang loose. This is going to be epic!

September 
15
 at 
5:30pm

Accelerating BioVenture Innovation Kickoff

RSVP to receive webinar link
Text goes here
X

Text Block #1

About Accelerating BioVenture Innovation:

Accelerating BioVenture Innovation (ABI) is a 12-week entrepreneurship training program that builds teams and business plans around patented technologies from Weill Cornell Medicine, Memorial Sloan Kettering Cancer Center and Rockefeller University. Each week participants learn how to take an invention the next step to commercialization, as well as valuable professional development skills. Each team is assigned 2-to-3 top-tier industry mentors. Participants may work on their own inventions or select one from the ABI Tri-I portfolio.

 

Who should participate? Principal Investigators, Clinicians, Postdocs, Graduate/Medical Students. The ABI course is also open to the broader life sciences entrepreneurial ecosystem.


BioVenture Alumni Companies Include:

https://onethree.bio/

https://pixorize.com/

https://goldilockstherapeutics.com/

https://biosleeptech.com/

https://c2i-genomics.com/

https://www.de-stroke.com/

https://pelex-med.com/

https://www.myiriscare.com/

and many more...!


Please click the link below to join the webinar:

https://weillcornell.zoom.us/j/99116804836

Passcode: 149914


Fill out this form to receive information on the upcoming program as a participant!


Fill out this form if you are interested in being an ABI Mentor


Watch our 2021 Startup Symposium, featuring Keynote Speaker, Bob Langer

Keynote Speaker

Robert Ang, MBBS, MBA
Chief Executive Officer, Vor Biopharma

Dr. Ang brings experience as a senior biotech executive and is formerly a physician, venture capitalist and strategy consultant. Prior to Vor, Dr. Ang was Chief Business Officer at Neon Therapeutics, serving as part of the early team that established the company prior to its Series A investment through IPO. Before Neon, he served as Senior Vice President of Business Development at Bavarian Nordic, where he was primarily responsible for conducting a $975 million transaction between the company and Bristol-Myers Squibb for PROSTVAC, a Phase 3 immuno-oncology asset. Prior to Bavarian Nordic, Dr. Ang served as Head of both Business Development and Medical Affairs for Cadence Pharmaceuticals and worked at Frazier Healthcare Ventures, a leading life sciences venture capital firm. At Frazier, he was involved in several pharmaceutical and biotechnology investments, including Cadence Pharmaceuticals (now Mallinckrodt), Incline Therapeutics (now The Medicines Company), Alnara Pharmaceuticals (now Eli Lilly) and Collegium Pharmaceuticals. Dr. Ang also has experience in strategy consulting at the Boston Consulting Group and has general surgical training. He holds an MBBS (Doctor of Medicine) from the University of Western Australia and an MBA with honors from Columbia Business School.


Image Grid Block #4



Inventors and innovators wanted!

Do you have an idea for a medical device but aren’t sure what to do next or how to produce it? Join us in the brand-new BioVenture eLab for an exciting evening to discuss medical device innovation as we begin a new initiative to gather like-minded individuals interested in the field.

 

All backgrounds are encouraged to attend: i.e., surgeons, clinicians, researchers, business, graduate students, engineers etc.

Dr. Srivastava is an experienced biotechnology executive and investment analyst. Dr. Srivastava was recently the Chief Financial and Strategy Officer for Abide Therapeutics. Prior to this, she was the Chief Financial and Strategy Officer for Intellia Therapeutics from April 2015 to December 2016. She played an integral role in helping start up Intellia’s financial operations and strategic direction, the Series B private funding, and the initial public offering.

Dr. Srivastava has fifteen years of experience as a stock analyst for biotechnology sector on Wall Street. She was the senior analyst and team leader of the biotechnology group at Goldman Sachs. Prior to that role, Dr. Srivastava was the senior biotechnology analyst at Morgan Stanley and ThinkEquity Partners, LLC, and began her career as a research associate at JP Morgan. Dr. Srivastava has also served as an independent strategy advisor to several high growth potential, therapeutic focused, biotechnology companies.

Dr. Srivastava received her PhD in neuroscience from New York University and her B.Sc from St. Xavier’s College in India.

Text Block #11

Starting your own business and picking the right niche in no time

Dr. Srivastava is an experienced biotechnology executive and investment analyst. Dr. Srivastava was recently the Chief Financial and Strategy Officer for Abide Therapeutics. Prior to this, she was the Chief Financial and Strategy Officer for Intellia Therapeutics from April 2015 to December 2016. She played an integral role in helping start up Intellia’s financial operations and strategic direction, the Series B private funding, and the initial public offering.

Dr. Srivastava has fifteen years of experience as a stock analyst for biotechnology sector on Wall Street. She was the senior analyst and team leader of the biotechnology group at Goldman Sachs. Prior to that role, Dr. Srivastava was the senior biotechnology analyst at Morgan Stanley and ThinkEquity Partners, LLC, and began her career as a research associate at JP Morgan. Dr. Srivastava has also served as an independent strategy advisor to several high growth potential, therapeutic focused, biotechnology companies.

Dr. Srivastava received her PhD in neuroscience from New York University and her B.Sc from St. Xavier’s College in India.

#BioVentureMedicalDeviceInnovationEvent
Share with Friends
Facebook
Twitter
LinkedIn
Link
Powered by
CONTACT THE ORGANIZER
Google   Outlook   iCal   Yahoo

RSVP

processing image...

Throwing your own event?

Make it awesome with Splash.
Check it out!
Google Icon
Google
Outlook Icon
Outlook
Apple Icon
Apple
Yahoo Icon
Yahoo